Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group

被引：0
|
作者：
Schmiegel, W. H.
Reinacher-Schick, A.
Freier, W.
Dietrich, G.
Arnold, D.
Kanzler, S.
Geissler, M.
Graeven, U.
Hegewisch-Becker, S.
Schmoll, H.
机构：
[1] Ruhr Univ, Bochum, Germany
[2] Ctr Oncol, Hildesheim, Germany
[3] Bietigheim Hosp, Bietigheim, Germany
[4] Martin Luther Univ Halle Wittenberg, Halle, Germany
[5] Johannes Gutenberg Univ Mainz, Mainz, Germany
[6] Community Hosp, Esslingen, Germany
[7] Maria Hilf Hosp, Monchengladbach, Germany
[8] Ctr Oncol, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study
    Hegewisch-Becker, S.
    Arnold, D.
    Lerchenmueller, C. A.
    Killing, B.
    Depenbusch, R.
    Steffens, C. -C
    Al-Batran, S. -E
    Lange, T.
    Dietrich, G.
    Stoehlmacher, J.
    Reinacher-Schick, A.
    Tannapfel, A.
    Quidde, J.
    Hinke, A.
    Schmoll, H. -J
    Graeven, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 99
  • [42] Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) Phase III study
    Punt, C.
    Douma, J.
    Honkoop, A.
    Wals, J.
    Erdkamp, F.
    de Jong, R.
    Rodenburg, C.
    Vreugdenhil, G.
    Akkermans-Vogelaar, J.
    Dalesio, O.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [43] Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC), an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
    Koopman, CJA
    Dalesio, M
    Douma, J
    Wals, J
    Honkoop, AH
    Erdkamp, FLG
    de Jong, RS
    Rodenburg, CJ
    Akkermans-Vogelaar, JM
    Punt, CJA
    ANNALS OF ONCOLOGY, 2006, 17
  • [44] A Swiss multicentre phase II study of capecitabine plus oxaliplatin (CAPOX) in combination with preoperative pelvic radiotherapy in patients (pts) with locally advanced rectal cancer
    Koeberle, D.
    Burkhard, R.
    Von Moos, R.
    Winterhalder, R.
    Hess, V.
    Heitzmann, F.
    Ruhstaller, T.
    Terraciano, L.
    Bieri, G.
    Toepfer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 244 - 244
  • [45] Irinotecan/capecitabine versus cisplatin/capecitabine in advanced or metastatic adenocarcinorna of the stomach or gastroesophageal junction:: Preliminary results of a randomized German AlO phase II-study
    Möhler, M
    Geissler, M
    Kanzler, S
    Raedle, J
    Ebert, M
    Fischbach, W
    Scheruebl, H
    Seufferlein, T
    Galle, PR
    Hoehler, T
    MEDIZINISCHE KLINIK, 2006, 101 (04) : A44 - A44
  • [46] A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Farr, Katherina Podlekareva
    Vestermark, Lene Weber
    Jensen, Helle Anita
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [47] SAFETY ANALYSIS OF AN INTERNATIONAL MULTI-CENTRE RANDOMISED PHASE II/III STUDY OF CAPECITABINE (CAP), BEVACIZUMAB (BEV) AND MITOMYCIN C (MMC) IN METASTATIC COLORECTAL CANCER (MCRC): AGITG MAX TRIAL
    Price, T. J.
    Gebski, V.
    van Hazel, G.
    Robinson, B.
    Broad, A.
    Ganju, V.
    Chua, Y.
    Wilson, K.
    Tunney, V.
    Tebbutt, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 127 - 127
  • [48] Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
    Larsen, Finn Ole
    Markussen, Alice
    Diness, Laura V.
    Nielsen, Dorte
    ONCOLOGY, 2018, 94 (01) : 19 - 24
  • [49] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [50] Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX plus FP plus BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
    Nagasaka, T.
    Inada, R.
    Ojima, H.
    Noura, S.
    Tanioka, H.
    Munemoto, Y.
    Shimada, Y.
    Ishibashi, K.
    Shindo, Y.
    Kagawa, Y.
    Tomibayashi, A.
    Okamoto, K.
    Tsuji, A.
    Tsuji, Y.
    Yamaguchi, S.
    Sawaki, A.
    Mishima, H.
    Shimokawa, M.
    Okajima, M.
    Yamaguchi, Y.
    ANNALS OF ONCOLOGY, 2019, 30
12345